首页> 外文期刊>中华医学杂志(英文版) >Liver support therapy with molecular adsorbents recirculating system in liver failure:a summary of 252 cases from 14 centers in China
【24h】

Liver support therapy with molecular adsorbents recirculating system in liver failure:a summary of 252 cases from 14 centers in China

机译:分子吸附剂再循环系统在肝衰竭中的肝支持治疗:来自中国14个中心的252例病例总结

获取原文
获取原文并翻译 | 示例
           

摘要

Background A liver support therapy,named molecular adsorbents recirculating system (MARS),has been used for more than 700 liver failure patients in China.We made here a summary to evaluate the effects of MARS treatment in different applications with emphasis on hepatitis B virus (HBV) based liver failure.Methods This report analyzed data of 252 patients (mean age (44.9±12.7) years) in three groups:acute severe hepatitis (ASH),subacute severe hepatitis (SSH) and chronic severe hepatitis (CSH).The largest group was CSH (156 patients,61.9%),and 188 patients (74.6%,188/252) were infected with HBV.Results MARS treatments were associated with significant reduction of albumin bound toxins and water-soluble toxins.Most of the patients showed a positive response with a significant improvement of multiple organ function substantiated by a significant increase in prothrombin time activity (PTA) and median arterial pressure (MAP).There was a decrease in hepatic encephalopathy (HE) grade and Child-Turcotte-Pugh (CTP) scale.Thirty-nine of 188 HBV patients (20.7%) dropped out of the commendatory consecutive therapy ending with lower survival of 43.6% while the rest of the 149 patients had a survival rate of 62.4%.Survival within the ASH and SSH groups were 81.2% and 75.0%,respectively.In the CSH group,end stage patients were predominant (65/151,43%),whereas the early and middle stage patients had a better prognosis:early stage survival,including orthotopic liver transplantation (OLT) survival of 91.7%,middle stage survival of 75%,end stage survival of 33.8%.Conclusions MARS continues to be the most favorable extracorporeal treatment for liver support therapy in China for a wide range of conditions,including the majority of hepatitis B related liver failure conditions.The appropriate application of MARS for the right indications and stage of hepatic failure,as well as the fulfillment of prescribed treatments,will lead to the optimal therapeutic result.
机译:背景肝支持疗法被称为分子吸附剂再循环系统(MARS),已在中国用于700多名肝功能衰竭患者。我们在此进行总结以评估MARS在不同应用中对乙型肝炎病毒的治疗效果(方法本报告分析了三组252例患者(平均年龄(44.9±12.7)岁)的数据,这些患者分为三组:急性重症肝炎(ASH),亚急性重症肝炎(SSH)和慢性重症肝炎(CSH)。最大的一组是CSH(156例,61.9%),其中188例(74.6%,188/252)被HBV感染。结果MARS治疗与白蛋白结合毒素和水溶性毒素的显着减少有关。凝血酶原时间活性(PTA)和中位数动脉压(MAP)显着增加,显示出阳性反应,多器官功能显着改善。肝性脑病(HE)等级和Child- Turcotte-Pugh(CTP)量表.188例HBV患者中有39例(20.7%)退出了推荐性连续治疗,最终生存率降低了43.6%,其余149例患者的生存率为62.4%。 ASH组和SSH组分别为81.2%和75.0%。在CSH组中,晚期患者占优势(65 / 151,43%),而早期和中期患者的预后较好:早期生存期包括原位肝移植(OLT)生存率91.7%,中期生存率75%,终末生存率33.8%。结论MARS仍然是中国在各种情况下最有利的肝支持治疗体外疗法,包括大多数B型肝炎相关的肝衰竭情况。正确使用MARS以适应肝适应症的正确适应症和分期,以及完成规定的治疗方法,都将获得最佳的治疗效果。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2008年第21期|2197-2201|共5页
  • 作者单位

    Therapeutic Blood Purification Research Center,University of Rostock,Germany;

    Therapeutic Blood Purification Research Center,University of Rostock,Germany;

    Department of Artificial Liver Therapy,Jinan Infectious Diseases Hospital,Jinan,Shandong 250021,China;

    Department of Artificial Liver Therapy,Jinan Infectious Diseases Hospital,Jinan,Shandong 250021,China;

    Xiangya Transplantation Medical Academy,Central South University,Changsha,Hunan 410013,China;

    Xiangya Transplantation Medical Academy,Central South University,Changsha,Hunan 410013,China;

    Department of Artificial Liver Therapy,Nanjing Second People's Hospital,Southeast University Medical College,Nanjing,Jiangsu 210003,China;

    Department of Artificial Liver Therapy,Nanjing Second People's Hospital,Southeast University Medical College,Nanjing,Jiangsu 210003,China;

    Division of Infectious Diseases,First Affiliated Hospital of Jiangxi Medical College,Nanchang,Jiangxi 330006,China;

    Division of Infectious Diseases,First Affiliated Hospital of Jiangxi Medical College,Nanchang,Jiangxi 330006,China;

    Institute of Digestive Diseases,Xijing Hospital,Fourth Military Medical University,Xi'an,Shaanxi 400038,China;

    Institute of Digestive Diseases,Xijing Hospital,Fourth Military Medical University,Xi'an,Shaanxi 400038,China;

    ICU & Artificial Liver Support Center,Beijing Ditan Hospital,Beijing 100011,China;

    ICU & Artificial Liver Support Center,Beijing Ditan Hospital,Beijing 100011,China;

    Institute of Hepatology,First Hospital,Xinjiang Medical University,Urmqi,Xinjiang 830000,China;

    Institute of Hepatology,First Hospital,Xinjiang Medical University,Urmqi,Xinjiang 830000,China;

    Department of Nephrology,Fudan University Zhongshan Hospital,Shanghai 200032,China;

    Department of Nephrology,Fudan University Zhongshan Hospital,Shanghai 200032,China;

    Department of Artificial Liver Therapy,Guangzhou No.8Hospital,Guangzhou,Guangdong 510060,China;

    Department of Artificial Liver Therapy,Guangzhou No.8Hospital,Guangzhou,Guangdong 510060,China;

    ITU & Blood Purification Center,First People's Hospital of Foshan,Foshan,Guangdong 528000,China;

    ITU & Blood Purification Center,First People's Hospital of Foshan,Foshan,Guangdong 528000,China;

    Tianjin First Central Hospital,Tianjin Organ Transplantation Institute,Tianjing 300192,China;

    Tianjin First Central Hospital,Tianjin Organ Transplantation Institute,Tianjing 300192,China;

    Department of Infectious Diseases,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China;

    Department of Infectious Diseases,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China;

  • 收录信息 中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 内科学;
  • 关键词

    liver failure; artificial liver; Hepatitis B;

    机译:肝功能衰竭;人工肝;乙型肝炎;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号